

Rokea A El-Azhary

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3234370/publications.pdf>

Version: 2024-02-01

54
papers

1,160
citations

361045

20
h-index

395343

33
g-index

54
all docs

54
docs citations

54
times ranked

1125
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival, Risk Factors, and Effect of Treatment in 101 Patients With Calciphylaxis. Mayo Clinic Proceedings, 2016, 91, 1384-1394.	1.4	145
2	Amyopathic dermatomyositis: Retrospective review of 37 cases. Journal of the American Academy of Dermatology, 2002, 46, 560-565.	0.6	139
3	Postoperative pyoderma gangrenosum (PG): The Mayo Clinic experience of 20 years from 1994 through 2014. Journal of the American Academy of Dermatology, 2015, 73, 615-622.	0.6	88
4	Histopathology of Calciphylaxis: Cohort Study With Clinical Correlations. American Journal of Dermatopathology, 2017, 39, 795-802.	0.3	59
5	Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996-2013. International Journal of Dermatology, 2017, 56, 405-414.	0.5	44
6	Calciphylaxis: A Disease of Pannicular Thrombosis. Mayo Clinic Proceedings, 2016, 91, 1395-1402.	1.4	42
7	Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: The Mayo Clinic experience, 1996 through 2013. Journal of the American Academy of Dermatology, 2016, 75, 931-939.	0.6	38
8	Sweet Syndrome as a Manifestation of Azathioprine Hypersensitivity. Mayo Clinic Proceedings, 2008, 83, 1026-1030.	1.4	37
9	A 10-Year Retrospective Study on Palladium Sensitivity. Dermatitis, 2009, 20, 208-213.	0.8	37
10	Retrospective Analysis of Tissue Plasminogen Activator as an Adjuvant Treatment for Calciphylaxis. JAMA Dermatology, 2013, 149, 63.	2.0	35
11	Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013. Journal of the American Academy of Dermatology, 2019, 80, 1658-1663.	0.6	35
12	Azathioprine: current status and future considerations. International Journal of Dermatology, 2003, 42, 335-341.	0.5	33
13	Bexarotene treatment of late-stage mycosis fungoides and SÅ©zary syndrome: Development of extracutaneous lymphoma in 6 patients—, Journal of the American Academy of Dermatology, 2005, 52, 991-996.	0.6	33
14	Cutaneous microemboli from hydrophilic polymer after endovascular procedures. Journal of the American Academy of Dermatology, 2015, 73, 666-671.	0.6	33
15	Experience of a year of adult hospital dermatology consultations. International Journal of Dermatology, 2015, 54, 1150-1156.	0.5	29
16	Direct oral anticoagulant medications in calciphylaxis. International Journal of Dermatology, 2017, 56, 1065-1070.	0.5	29
17	Cutaneous manifestations of graft-versus-host disease: role of the dermatologist. International Journal of Dermatology, 2017, 56, 131-140.	0.5	28
18	Pediatric Hospital Dermatology: Experience with Inpatient and Consult Services at the Mayo Clinic. Pediatric Dermatology, 2013, 30, 433-437.	0.5	24

#	ARTICLE	IF	CITATIONS
19	Acute cutaneous graft-versus-host disease compared to drug hypersensitivity reaction with vacuolar interface changes: a blinded study of microscopic and immunohistochemical features. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 39-45.	0.7	23
20	Antihistone antibodies in linear scleroderma variants. <i>International Journal of Dermatology</i> , 2006, 45, 1296-1299.	0.5	22
21	Kaposi varicelliform eruption in patients with Darier disease: A 20-year retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 481-484.	0.6	21
22	Treatment of late-stage Sezary syndrome with 2-Chlorodeoxyadenosine. <i>International Journal of Dermatology</i> , 2002, 41, 352-356.	0.5	16
23	Dermatologic manifestations of solid organ transplantation-associated graft-versus-host disease: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 1097-1101.e1.	0.6	16
24	A new patient education approach in contact allergic dermatitis: the Contact Allergen Replacement Database (CARD)*. <i>International Journal of Dermatology</i> , 2004, 43, 278-280.	0.5	14
25	Do Antihistone Autoantibodies Reflect Disease Activity in Linear Scleroderma?. <i>Archives of Dermatology</i> , 2004, 140, 759-60.	1.7	12
26	Thioguanine Nucleotides and Thiopurine Methyltransferase in Immunobullous Diseases. <i>Archives of Dermatology</i> , 2009, 145, 644-52.	1.7	12
27	Contact allergen avoidance program: A topical skin care product database. <i>American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society</i> , 2000, 11, 243-247.	0.4	11
28	Oral bexarotene in a therapy-resistant Sezary syndrome patient: observations on Sezary cell compartmentalization. <i>International Journal of Dermatology</i> , 2005, 44, 25-28.	0.5	10
29	The inevitability of change. <i>Clinics in Dermatology</i> , 2019, 37, 4-11.	0.8	9
30	Allergic contact dermatitis to epoxy resin in immersion oil for light microscopy. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 954-955.	0.6	8
31	Evaluating the validity of subclassifying warfarin-associated nonuremic calciphylaxis: a retrospective cohort study. <i>International Journal of Dermatology</i> , 2018, 57, 572-574.	0.5	8
32	Treatment of severe drug reactions by hemodialysis. <i>International Journal of Dermatology</i> , 2018, 57, 177-182.	0.5	8
33	Clinical and histopathologic manifestations of solid organ transplantation-associated graft-versus-host disease involving the skin: A single-center retrospective study. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 817-823.	0.7	7
34	Differences between Stevens-Johnson syndrome versus toxic epidermal necrolysis. <i>International Journal of Dermatology</i> , 2021, 60, 53-59.	0.5	6
35	Sclerotherapy of spider veins using the accurate depth-gauge collagen needle. <i>International Journal of Dermatology</i> , 2008, 47, 205-206.	0.5	5
36	Missed opportunities in residency education: The role of hospital dermatology. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 677-678.	0.6	5

#	ARTICLE	IF	CITATIONS
37	EFFICACY OF CONTACT ALLERGEN REPLACEMENT DATABASE (CARD) IN THE TREATMENT OF ALLERGIC CONTACT DERMATITIS SECONDARY TO TOPICAL SKIN CARE PRODUCT USE. <i>American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society</i> , 2001, 12, 124.	0.4	4
38	Exfoliative erythroderma after tumor necrosis factor- α inhibitor therapy. <i>International Journal of Dermatology</i> , 2016, 55, e214-e215.	0.5	4
39	Adalimumab-induced erythrodermic reactions. <i>International Journal of Dermatology</i> , 2019, 58, e204-e206.	0.5	4
40	Chemotherapy-induced skin toxicity and capillary leak syndrome. <i>International Journal of Dermatology</i> , 2019, 58, 856-860.	0.5	4
41	Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 738-746.	0.6	4
42	Filling a critical practice gap: experience with a dermatology day treatment center at Mayo Clinic. <i>International Journal of Dermatology</i> , 2015, 54, 600-604.	0.5	3
43	Disseminated intravascular coagulopathy: a complication of Stevensâ€ˆJohnson syndrome/toxic epidermal necrolysis. <i>International Journal of Dermatology</i> , 2021, 60, 185-189.	0.5	3
44	Pharmacogenetics in dermatology: a patient-centered update. <i>International Journal of Dermatology</i> , 2013, 52, 1005-1012.	0.5	2
45	The last bastion of collegiality: the peer-review process in the era of open access. <i>International Journal of Dermatology</i> , 2016, 55, 247-248.	0.5	2
46	Immunophenotypic and molecular comparison between allogeneic and autologous graft-versus-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1087-1091.	0.7	2
47	Prevalence of allergen sensitization detected by patch tests. <i>Allergy and Asthma Proceedings</i> , 2018, 39, 240-244.	1.0	2
48	Anticipating and preventing infection in patients treated with immunosuppressive medications for dermatologic indications: A dermatologist's checklist. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, e125-e126.	0.6	1
49	Cutaneous manifestations of immunoglobulin G-related disease: what dermatologists need to know. <i>International Journal of Dermatology</i> , 2015, 54, 377-382.	0.5	1
50	Strengthening the Case for the Role of Thrombophilia in Calciphylaxis. <i>JAMA Dermatology</i> , 2018, 154, 970.	2.0	1
51	Melanoma in a patient with previously unrecognized Birt-Hogg-DubÃ© syndrome. <i>JAAD Case Reports</i> , 2019, 5, 947-952.	0.4	1
52	Retrospective analysis of 578 inpatient dermatology consultations in hematology and hematopoietic stem cell transplant patients. <i>International Journal of Dermatology</i> , 2021, 60, 1385-1391.	0.5	1
53	Chemokine Responses in Palladium-Induced Lichenoid Eruption. <i>Dermatitis</i> , 2012, 23, 180-181.	0.8	0
54	Focus Africa. <i>International Journal of Dermatology</i> , 2020, 59, 519-519.	0.5	0